Continuous DC-CIK Infusions Restore CD8+ Cellular Immunity, Physical Activity and Improve Clinical Efficacy in Advanced Cancer Patients Unresponsive to Conventional Treatments |
Zhao, Yan-Jie
(Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines)
Jiang, Ni (Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines) Song, Qing-Kun (Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines) Wu, Jiang-Ping (Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines) Song, Yu-Guang (Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines) Zhang, Hong-Mei (Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines) Chen, Feng (Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines) Zhou, Lei (Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines) Wang, Xiao-Li (Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines) Zhou, Xin-Na (Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines) Yang, Hua-Bing (Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines) Ren, Jun (Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Lab of Therapeutic Cancer Vaccines) Lyerly, Herbert Kim (Department of Surgery, Duke University Medical Center) |
1 | Bradley M, Zeytun A, Rafi-Janajreh A, et al (1998). Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells. Blood, 92, 4248-55. |
2 | Chen R, Deng X, Wu H, et al (2014). Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis. Int Immunopharmacol, 22, 451-64. DOI |
3 | Choudhury A, Palma M, Mellstedt H (2008). The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. Clin Lung Cancer, 9, 37-44. DOI |
4 | Danielle D, Parker P, Fouladi R, et al (2003). The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology, 12, 453-62. DOI |
5 | Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 (Internet). Lyon, France: international agency for research on cancer; Available from: http://globocan.iarc.fr, accessed on day/month/year. |
6 | Gao D, Li C, Xie X, et al (2014). Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One, 9, 93886. DOI |
7 | Han RX, Liu X, Pan P, et al (2014). Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis. PLoS One, 9, 108958. DOI |
8 | Heusel J, Wesselschmidt R, Shresta S, et al (1994). Cytotoxic lymphocytes require granzymeB for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell, 76, 977-87. DOI |
9 | Jin C, Li J, Wang Y, et al (2014). Impact of cellular immune function on prognosis of lung cancer patients after cytokine-induced killer cell therapy. Asian Pac J Cancer Prev, 15, 6009-14. DOI |
10 | Kagi D, Ledermann B, Burki K, et al (1994). Cytotoxicity mediated by T cells and natural killer cells is greatly impaired inperforin-deficient mice. Nature, 5, 31-7. |
11 | Liu P, Chen L, Huang X (2009). The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother Radiopharm, 24, 91-8. DOI |
12 | Marten A, Ziske C, Schottker B, et al (2001). Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother, 24, 502-10. DOI |
13 | Ren J, Di L, Song G, et al (2013). Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Transl Oncol, 15, 780-8. DOI |
14 | Schmidt-Wolf IG, Lefterova P, Johnston V, et al (1996). Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol, 169, 85-90. DOI |
15 | Shi L, Zhou Q, Wu J, et al (2012). Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother, 61, 2251-9. DOI |
16 | Shi SB, Tang XY, Tian J, et al (2014). Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer. J Immunother, 37, 250-5. DOI |
17 | Song G, Wang X, Jia J, et al (2013). Elevated level of peripheral CD8(+)CD28(-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. Cancer Immunol Immunother, 62, 1123-30. DOI |
18 | Wang ZX, Cao JX, Wang M, et al (2014c). Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. Cytotherapy, 16, 934-45. DOI |
19 | Wang D, Zhang B, Gao H, et al (2014a). Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer, 14, 251. DOI |
20 | Wang ZX, Cao JX, Liu ZP, et al (2014b). Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis. World J Gastroenterol, 20, 1095-106. DOI ScienceOn |
21 | Zhao Y, Song Y, Zhang H, et al (2014). Clinical analysis of patients suffering from advanced malignancy with survival time less than 3 months by DC-CIK cells. Cancer Res Prev Treat, 41, 397-400. |